Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deleted in azoospermia protein 3 (DAZ3) is a member of the DAZ gene family, encoding an RNA-binding protein that plays a critical role in human spermatogenesis and male fertility[2][3][5]. DAZ3 expression is limited to premeiotic germ cells, particularly spermatogonia, where it regulates the translation of mRNAs essential for germ cell development and differentiation[1][2][5]. The DAZ gene family is located on the Y chromosome and is a candidate for the azoospermia factor (AZF) region, with loss or microdeletion of DAZ3 contributing to defects in sperm production and male infertility[2][5]. The encoded protein possesses a conserved RNA recognition motif (RRM) and DAZ repeats, facilitating interactions with target mRNAs involved in meiosis and germ cell maintenance[1][3][5]. DAZ3 does not function as a receptor, enzyme, transporter, or canonical drug target and there are no approved drugs directed at this protein; its primary significance is diagnostic or genetic in cases of male infertility[2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deleted in azoospermia protein 3 (DAZ3).